Otsuka Holdings Co., Ltd.
OTSKF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$38.38B
Close$
$107.66
47.2% upside
Current Fair Value
47.2% upsideUndervalued by 47.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $38.38 Billion |
|---|---|
| Enterprise Value | $-182,609,376,205.00 |
| Annual dividend | $1.06 |
| Dividend yield | 1.41% |
| Earnings per Share | $685.44 |
| Beta | -0.05 |
| Outstanding Shares | 524,689,000 |
Return
| Return on Equity | 12.10% |
|---|---|
| Return on Assets | 8.92% |
| Return on Invested Capital | 13.29% |
Valuation & Multiples
| P/E Ratio | 22.53 |
|---|---|
| PEG | -143.7 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 2.23 |
| Enterprise Value to EBIT | 12.5 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 30, 2026
EPS Estimate
$1.17
Consensus analyst estimateRevenue Estimate
$4.44 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 12, 2027
EPS Estimate
$0.61
Consensus analyst estimateRevenue Estimate
$4.53 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Otsuka Holdings Co., Ltd.
37,758 employees
CEO: Makoto Inoue
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal s...